Merck & Co is one of the investors set to exit antibody drug developer Visterra after Otsuka Pharmaceutical agreed to buy the company for $430m.

Unternehmertum Venture Capital Partners has agreed to sell its shares in AMW as part of an acquisition led by Hybio Pharmaceutical and Yunfeng Capital.

CBRE and corporate venturing units GV and M12 exited as Siemens bought Building Robotics, the developer of building environmental control app Comfy.

BMW i Ventures is set to exit EV charger developer Chargemaster in a purchase of undisclosed size by BP.

Natural language processing technology developer Bloomsbury AI has joined Facebook for up to $30m, enabling UCL Technology Fund to exit.

Efficient Drivetrains, which had amassed $17.5m in capital, makes drivetrain systems for electric and hybrid-powered automotive vehicles based on research from UC Davis.

The Axel Johnson-backes apparel fitting technology developer has been bought by a group of Japanese investors for $12.7m.

Avexis, which is commercialising research from Ohio State University and Nationwide Children's Hospital, has been acquired by Novartis for $8.7bn.